Treatment of cluster headache with topiramate: effects and side-effects in five patients.

Treatment of cluster headache with topiramate: effects and side-effects in five patients. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Treatment of cluster headache with topiramate: effects and side-effects in five patients. Abstract Text:

A M Rapoport,M E Bigal,S J Tepper,F D Sheftell,

We report on clinical experience with topiramate in the prophylactic treatment of three patients with chronic and two patients with episodic, otherwise therapy-resistant, cluster headache. Patients were treated with daily doses of 75-200 mg topiramate. Topiramate was effective in three patients but proved ineffective and also caused intolerable side-effects in two patients. Topiramate may have prophylactic properties for treating cluster headache at lower doses than needed in epilepsy therapy, but its clinical value is limited due to central nervous system side-effects.

Treatment of cluster headache with topiramate: effects and side-effects in five patients. Publishing Authors By Initials

AM Rapoport,ME Bigal,SJ Tepper,FD Sheftell,

For similar persons: age groups: adult: middle aged research abstracts see: persons: age groups: adult: middle aged research

PUBMED ID PMID:

MEDLINE DATE:

Treatment of cluster headache with topiramate: effects and side-effects in five patients. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Cephalalgia : an international journal of headache

VOLUME: 22

Page Numbers: 186-9

Journal Abbreviation: Cephalalgia

ISSN: 0333-1024

DAY: 11

MONTH: Apr

YEAR: 2002

Treatment of cluster headache with topiramate: effects and side-effects in five patients. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8200710

Treatment of cluster headache with topiramate: effects and side-effects in five patients. Keywords Mesh Terms:

KEYWORDS: Middle Aged

MESH TERMS: therapeutic use

Chemical & Substance for Abstract: Treatment of cluster headache with topiramate: effects and side-effects in five patients. Information

Substance Name: topiramate

Registry Number: 97240-79-4

Grant and Affiliation Information for Treatment of cluster headache with topiramate: effects and side-effects in five patients.

AFFILIATION: Department of Neurology, Klinikum Grosshadern, Ludwig-Maximilians University, Munich, Germany. SFOE@nefo.med.uni-muenchen.de

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Cephalalgia

REFSOURCE: Cephalalgia. 2003 Feb;23(1):69-70; autho

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Treatment of cluster headache with topiramate: effects and side-effects in five patients Related Publications

• A concentric-ring equivalent phased array method to model fields of large axisymmetric ultrasound transducers.
• Barry Straube on the CMS Office of Clinical Standards and Quality. Interview by Pamela K Scarrow.
• Botulinum toxin type-A therapy in cluster headache: an open study.
• Chlamydia pneumoniae infection of aortic smooth muscle cells reduces platelet-derived growth factor receptor-beta expression.
• Commentary. The imperatives for change in the US health care payment and delivery systems are clear.
• Decreased sTNF-RI in migraine patients?
• FES cycling reduces spastic muscle tone in a patient with multiple sclerosis.
• Motor cortex excitability in patients with migraine with aura and hemiplegic migraine.
• Partial improvement of headache in a patient with spontaneous cervical cerebrospinal fluid (CSF) leakage after lumbar blood patch.
• Recognition and evaluation of emotional prosody in individuals with generalized social phobia: a pilot study.
• Reversible dementia and corresponding CSF alterations due to intraspinal lumbosacral metastasis of a prostate carcinoma.
• T-cell subsets and expression of integrins in peripheral blood of patients with migraine.
• Treatment of cluster headache with topiramate: effects and side-effects in five patients.
• Velocity scaling of cue-induced smooth pursuit acceleration obeys constraints of natural motion.
• [Demonstration of immunoglobulins, glycoproteins and beta 2 microglobulin in ovarian cysts and cystic ovarian tumors]
• [Detection of pregnancy-specific beta 1-glycoprotein (SP1), of proteins of the "pregnancy zone" (PZ), of pregnancy-associated plasma protein A (PAPP-A) with 24-hour radial immunodiffusion. Detection of pregnancy-specific beta 1-glycoprotein (SP1) with tur
• [Detection of pregnancy-specific beta 1-glycoproteins (SP1) and pregnancy-associated plasma protein A (PAPP-A) in maternal serum. Diagnostic significance in intrauterine fetal retardation]
• [Detection of secretory IgA in urine of patients with urinary tract infection in pregnancy and puerperium (author's transl)]
• [Detection of secretory immunoglobulin A in cervical secretion and in cervicovaginal irrigation fluids]
• [Detection of secretory immunoglobulin A in vaginal fluid of hysterectomised women]
• [Estimation of secretory immunoglobulin A in serum of pregnant women (author's transl)]
• [Immunoglobulin M and alpha 2-macroglobulin in the amniotic fluid in neural tube defects]
• [Maternal serum IgA in intrauterine fetal growth retardation]
• [Mission oriented diagnostic real-time PCR.]
• [Not Available.]
• [Primary headaches and the influence of inflammatory diseases of the CNS and their respective immunmodulatory therapy]
• [Relation of AFP and glucose in amniotic fluid]
• [Secretory immunoglobulin A (S-IgA) in amniotic fluid and in pharyngeal mucus and urine of newborn infants]
• [Secretory immunoglobulin A (S-IgA)/immunoglobulin A (IgA) ratio in cervico-vaginal lavage fluids]
• [Serum concentration of pregnancy-associated alpha 2-glycoprotein (alpha 2-PAG, protein of pregnancy zone, PZ) in patients with dermatological diseases (author's transl)]